5kits zhao

Calendar

January 2011
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Pages

Archives

Blogroll






 

This week’s Science has a thought-provoking article charting how several of the world’s biggest pharmaceutical companies have canned their development of psychiatric drugs, citing the medications as unlikely to be profitable given the difficulties in understanding the neurobiology of mental illness.

On 4 February, GlaxoSmithKline (GSK) announced that it planned to pull the plug on drug discovery in some areas of neuroscience, including pain and depression. A few weeks later, news came that AstraZeneca was closing research facilities in the United States and Europe and ceasing drug-discovery work in schizophrenia, bipolar disorder, depression, and anxiety.

These cutbacks by two of the top players in drug development for disorders of the central nervous system have raised concerns that the pharmaceutical industry is pulling out, or at least pulling back, in this area. In direct response to the cuts at GSK and AstraZeneca, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders organized a meeting in late June that brought together leaders from government, academia, and private foundations to take stock.

Read in Full:  http://mindhacksblog.wordpress.com/2010/08/03/is-big-pharma-abandoning-psychiatry/



Leave a Reply

*